Can a simple blood test guide myeloma treatment and spare some patients from transplant?
NCT ID NCT05231629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized approach for people newly diagnosed with multiple myeloma. After initial treatment, patients are grouped based on whether their cancer is deeply suppressed (MRD-negative) or not. Those with deep response may receive extra drug cycles instead of a stem cell transplant, while others get a transplant plus newer drugs. The goal is to see if this tailored strategy can achieve and maintain the best possible remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) and teclistamab
What this could lead to
If successful, this could help tailor treatment for multiple myeloma patients, potentially allowing some to avoid intensive transplant while maintaining deep remission.
What could go wrong
This is a Phase 2 trial with 300 participants, so results are preliminary. The approach may not improve outcomes for all patients, and side effects from the drug combinations could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Wisconsin - Carbone
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••